TJ396B - A process for resolving a mixture of human dnase (variants), purified deamidated human dnase, purified non-deamidated human dnase, a pharmaceutical composition for reducing viscoelasticity of purulentmaterial (variants), a method for the treatment o f a patient suffering from accumulation of purulent material (variants), a method for the treatment of a patient suffering from cystic fibrosis, bronchitis, pneumonia. - Google Patents

A process for resolving a mixture of human dnase (variants), purified deamidated human dnase, purified non-deamidated human dnase, a pharmaceutical composition for reducing viscoelasticity of purulentmaterial (variants), a method for the treatment o f a patient suffering from accumulation of purulent material (variants), a method for the treatment of a patient suffering from cystic fibrosis, bronchitis, pneumonia.

Info

Publication number
TJ396B
TJ396B TJ96000330A TJ96000330A TJ396B TJ 396 B TJ396 B TJ 396B TJ 96000330 A TJ96000330 A TJ 96000330A TJ 96000330 A TJ96000330 A TJ 96000330A TJ 396 B TJ396 B TJ 396B
Authority
TJ
Tajikistan
Prior art keywords
variants
human dnase
treatment
patient suffering
purified
Prior art date
Application number
TJ96000330A
Other languages
English (en)
Inventor
John Frenz
Steven J Shire
Mary B Sliwkowski
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of TJ396B publication Critical patent/TJ396B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/814—Enzyme separation or purification
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/814—Enzyme separation or purification
    • Y10S435/815—Enzyme separation or purification by sorption

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
TJ96000330A 1992-06-08 1993-05-28 A process for resolving a mixture of human dnase (variants), purified deamidated human dnase, purified non-deamidated human dnase, a pharmaceutical composition for reducing viscoelasticity of purulentmaterial (variants), a method for the treatment o f a patient suffering from accumulation of purulent material (variants), a method for the treatment of a patient suffering from cystic fibrosis, bronchitis, pneumonia. TJ396B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/895,300 US5279823A (en) 1992-06-08 1992-06-08 Purified forms of DNASE
PCT/US1993/005136 WO1993025670A1 (en) 1992-06-08 1993-05-28 Purified forms of dnase

Publications (1)

Publication Number Publication Date
TJ396B true TJ396B (en) 2004-12-29

Family

ID=25404292

Family Applications (1)

Application Number Title Priority Date Filing Date
TJ96000330A TJ396B (en) 1992-06-08 1993-05-28 A process for resolving a mixture of human dnase (variants), purified deamidated human dnase, purified non-deamidated human dnase, a pharmaceutical composition for reducing viscoelasticity of purulentmaterial (variants), a method for the treatment o f a patient suffering from accumulation of purulent material (variants), a method for the treatment of a patient suffering from cystic fibrosis, bronchitis, pneumonia.

Country Status (30)

Country Link
US (4) US5279823A (ro)
EP (2) EP0644932B1 (ro)
JP (1) JP3383307B2 (ro)
KR (2) KR100302092B1 (ro)
AT (2) ATE195340T1 (ro)
AU (1) AU682822B2 (ro)
BG (1) BG62335B1 (ro)
BR (1) BR9306670A (ro)
CA (1) CA2137237C (ro)
CZ (1) CZ293105B6 (ro)
DE (3) DE69334317D1 (ro)
DK (1) DK0644932T3 (ro)
ES (1) ES2150447T3 (ro)
FI (1) FI945549L (ro)
GB (1) GB2282140B (ro)
GE (1) GEP20002300B (ro)
GR (1) GR3034718T3 (ro)
HU (1) HU219549B (ro)
IL (1) IL105724A (ro)
MD (1) MD960288A (ro)
NO (1) NO318644B1 (ro)
NZ (1) NZ253559A (ro)
PL (1) PL175873B1 (ro)
PT (1) PT644932E (ro)
RO (1) RO117188B1 (ro)
RU (1) RU2238320C2 (ro)
SK (1) SK282957B6 (ro)
TJ (1) TJ396B (ro)
UA (1) UA46693C2 (ro)
WO (1) WO1993025670A1 (ro)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007572A1 (en) * 1988-12-23 1990-07-12 Genentech, Inc. HUMAN DNase
US5279823A (en) 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE
ATE401394T1 (de) * 1994-03-04 2008-08-15 Genentech Inc Verbesserte dnase flüssige lösungen
WO1995023613A1 (en) * 1994-03-04 1995-09-08 Genentech, Inc. PHARMACEUTICALLY ACCEPTABLE DNase FORMULATION
US6251648B1 (en) 1998-04-03 2001-06-26 Human Genome Sciences, Inc. Gene encoding human Dnase
WO1995030428A1 (en) * 1994-05-05 1995-11-16 Human Genome Sciences, Inc. Human dnase
US5830744A (en) * 1995-06-06 1998-11-03 Human Genome Sciences, Inc. Gene encoding human Dnase
US5602110A (en) * 1994-08-31 1997-02-11 Case Western Reserve University Method and composition for treating cystic fibrosis
DE69522799T2 (de) * 1994-09-06 2002-06-20 Seiichi Tanuma Neuartige desoxyribonuklease
US5863563A (en) * 1994-10-20 1999-01-26 Alphagene Inc. Treatment of pulmonary conditions associated with insufficient secretion of surfactant
SK284191B6 (sk) 1995-02-24 2004-10-05 Genentech, Inc. Aktín-rezistentný variant humánnej DNázy I
US6348343B2 (en) 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
NZ331063A (en) * 1996-02-05 2000-03-27 Inc Genentech Isolated nucleotide sequences encoding for mature LS- DNase which is resistant to actin inhibition
US6482626B2 (en) * 1996-02-05 2002-11-19 Genentech, Inc. Human DNase
US6391607B1 (en) 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
BRPI9910332B8 (pt) * 1998-05-06 2021-05-25 Genentech Inc método para purificação de um polipeptídio a partir de uma composição
US8820316B2 (en) * 2000-02-11 2014-09-02 Respironics Respiratory Drug Delivery (Uk) Ltd Drug delivery apparatus
AU3500901A (en) * 2000-02-11 2001-08-20 Medic Aid Ltd Drug delivery apparatus
AU2001275191A1 (en) * 2000-05-31 2001-12-11 Chiron Corporation Method for the purification of alphavirus replicon particles
MD20010375A (ro) * 2001-11-19 2003-06-30 АНДРИЕВСКИ Сергей Malaxor
MD2260C2 (ro) * 2001-11-22 2004-03-31 АНДРИЕВСКИ Сергей Malaxor
LT1543038T (lt) 2002-09-11 2017-07-10 Genentech, Inc. Baltymo gryninimas
US7067298B2 (en) * 2003-03-31 2006-06-27 Ambion, Inc. Compositions and methods of using a synthetic Dnase I
US7595179B2 (en) 2004-04-19 2009-09-29 Applied Biosystems, Llc Recombinant reverse transcriptases
US20080160577A1 (en) * 2005-02-04 2008-07-03 Glaxo Group Limited Optimization of Heterologous Polypeptide Expression
KR100655438B1 (ko) * 2005-08-25 2006-12-08 삼성전자주식회사 자기 기억 소자 및 그 형성 방법
WO2007143206A2 (en) * 2006-06-02 2007-12-13 Epicentre Technologies Compositions and methods for removal of dna from a sample
AU2007311444B2 (en) * 2006-10-18 2012-11-29 Periness Ltd. Method and pharmacological composition for the diagnosis and treatment of male sub-fertility
CN105315323A (zh) * 2007-10-30 2016-02-10 健泰科生物技术公司 通过阳离子交换层析进行的抗体纯化
WO2009123950A2 (en) * 2008-03-31 2009-10-08 The Trustees Of The University Of Pennsylvania Chimera comprising bacterial cytotoxin and methods of using the same
US9226976B2 (en) 2011-04-21 2016-01-05 University Of Massachusetts RAAV-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
US9603906B2 (en) 2012-02-01 2017-03-28 Protalix Ltd. Inhalable liquid formulations of DNase I
CN103920144B (zh) * 2013-01-15 2016-09-14 吴庄民 重组人的脱氧核糖核酸酶i的新应用
KR20170026521A (ko) * 2014-06-25 2017-03-08 제이에이치엘 바이오테크 인코포레이티드 단백질의 정제를 위한 방법 및 시약
WO2016067944A1 (ja) 2014-10-31 2016-05-06 Ｊｃｒファーマ株式会社 組換えヒトＤＮａｓｅＩの製造方法
US20180214576A1 (en) * 2015-07-28 2018-08-02 University Of Massachusetts Transgenic expression of dnasei in vivo delivered by an adeno-associated virus vector
WO2017139643A1 (en) 2016-02-12 2017-08-17 University Of Massachusetts Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
TWI826360B (zh) 2016-11-17 2023-12-21 美商艾歐凡斯生物治療公司 殘餘腫瘤浸潤性淋巴細胞及製備和使用彼之方法
EP3351263A1 (en) 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmaceutical preparation for treating or preventing tissue adhesion
WO2021244964A1 (en) 2020-06-01 2021-12-09 Black Cat Bio Limited Compositions and methods for treating infections and netopathy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2801956A (en) * 1954-08-24 1957-08-06 Merck & Co Inc Process for preparing pancreatic desoxyribonuclease
US2834710A (en) * 1955-06-29 1958-05-13 Merck & Co Inc Pancreatic desoxyribonuclease penicillin composition and process of preparation
US3208908A (en) * 1961-11-16 1965-09-28 Parke Davis & Co Fibrinolysin-desoxyribonuclease for enzymatic debridement
US3663690A (en) * 1969-08-12 1972-05-16 Hoechst Co American Mucolytic composition and method of treatment of broncho-pulmonary disorders therewith
CA1059937A (en) * 1975-03-25 1979-08-07 Canada Packers Limited Isolation and purification of deoxyribonuclease
US5077211A (en) * 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
WO1990007572A1 (en) * 1988-12-23 1990-07-12 Genentech, Inc. HUMAN DNase
US5279823A (en) * 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE

Also Published As

Publication number Publication date
EP1013284A3 (en) 2000-08-30
WO1993025670A1 (en) 1993-12-23
DE69329200T2 (de) 2001-04-26
GB2282140A (en) 1995-03-29
IL105724A (en) 1997-06-10
UA46693C2 (uk) 2002-06-17
US6440412B1 (en) 2002-08-27
IL105724A0 (en) 1993-09-22
HUT70468A (en) 1995-10-30
ATE455557T1 (de) 2010-02-15
PL175873B1 (pl) 1999-02-26
DK0644932T3 (da) 2001-01-02
SK282957B6 (sk) 2003-01-09
BG99234A (bg) 1995-07-28
BG62335B1 (bg) 1999-08-31
MD960288A (ro) 1998-01-31
US5279823A (en) 1994-01-18
ATE195340T1 (de) 2000-08-15
GEP20002300B (en) 2000-11-25
US5783433A (en) 1998-07-21
KR100323357B1 (ko) 2002-02-19
EP1013284B1 (en) 2010-01-20
GB9423695D0 (en) 1995-01-11
HU219549B (hu) 2001-05-28
NO944752D0 (no) 1994-12-08
AU682822B2 (en) 1997-10-23
RO117188B1 (ro) 2001-11-30
SK149594A3 (en) 1996-01-10
KR100302092B1 (ko) 2001-10-22
US6932965B2 (en) 2005-08-23
NZ253559A (en) 1996-11-26
DE4392749T1 (de) 1995-07-20
PT644932E (pt) 2001-02-28
CA2137237A1 (en) 1993-12-23
BR9306670A (pt) 1998-12-08
GB2282140B (en) 1996-04-17
AU4398193A (en) 1994-01-04
DE69329200D1 (de) 2000-09-14
FI945549A0 (fi) 1994-11-25
ES2150447T3 (es) 2000-12-01
HU9403512D0 (en) 1995-02-28
NO318644B1 (no) 2005-04-25
US20030077267A1 (en) 2003-04-24
NO944752L (no) 1994-12-08
EP1013284A2 (en) 2000-06-28
CA2137237C (en) 2004-10-26
FI945549A7 (fi) 1994-11-25
CZ293105B6 (cs) 2004-02-18
CZ303294A3 (en) 1995-06-14
EP0644932A1 (en) 1995-03-29
JP3383307B2 (ja) 2003-03-04
FI945549L (fi) 1994-11-25
GR3034718T3 (en) 2001-01-31
EP0644932B1 (en) 2000-08-09
DE69334317D1 (de) 2010-03-11
RU94046424A (ru) 1997-03-10
JPH07507455A (ja) 1995-08-24
RU2238320C2 (ru) 2004-10-20

Similar Documents

Publication Publication Date Title
GB2282140B (en) Purified forms of dnase
EP0206497A3 (en) Process for the preparation of therapeutic nucleosides
CA2163112A1 (en) A coagulation factor viii formulation
ATE223230T1 (de) Pulmonäre verabreichung des löslichen komplement- receptors typ 1 scr1
GB8622194D0 (en) Therapeutic nucleosides
IL79379A0 (en) Carboxylic acid derivatives,process for the preparation thereof and pharmaceutical compositions containing them
AU1412088A (en) Therapeutic nucleosides
PT82499A (en) Process for the preparation of inhibitors of carbonic anhydrage and of pharmaceutical compositions containing the same
IL83775A (en) Amino acid esters and amides of fumaric acid and pharmaceutical compositions containing them for use in the treatment of psoriasis
MY104124A (en) Therapeutic compounds.
FR2592793A1 (fr) Association de sulpiride et de diazepam a titre de composition pharmaceutique, notamment utile dans le traitement des manifestations fonctionnelles digestives liees au stress, et son utilisation pour la preparation de ladite composition.